Although the possible consequences of such genetic variations remain to be confirmed in CAD, clinical studies have suggested that Fcγ-RIIIa polymorphism may explain the variability in the response to rituximab therapy in WM [80]. This evidence concerns the gene FCGR3A and cold agglutinin disease.